Factor Bioscience
Factor Bioscience is dedicated to unleashing the potential of cell engineering to treat disease and improve health. With over a decade of experience and more than 150 patents, the company develops advanced technologies such as mRNA, gene editing, cell reprogramming, and nucleic acid delivery to create innovative allogeneic cell therapies. They prioritize collaboration with strategic partners to accelerate the development of transformational medicines. The company actively engages in pioneering research projects, including developing gene-edited pluripotent stem cell lines and scalable differentiation processes for cancer-fighting lymphocytes, as well as collaborations to develop cell therapies for oncology, autoimmune, and neurological diseases. Factor Bioscience is committed to revolutionizing patient care through curiosity, discovery, and collaboration.
Industries
Nr. of Employees
small (1-50)
Factor Bioscience
Cambridge, Massachusetts, United States, North America
Products
Preclinical mesenchymal‑like cell therapy candidates
Cell therapy candidates derived via mRNA‑based reprogramming and directed differentiation workflows intended for preclinical evaluation in inflammatory and regenerative indications.
Preclinical engineered immune effector cell candidates
Defined immune cell populations produced from pluripotent or reprogrammed sources for oncology preclinical programs, including lymphocyte and macrophage‑like populations.
Delivery reagent families for nucleic acid applications
Chemical reagent families, including ionizable and fusogenic lipids and polymer reagents, developed to improve cellular uptake and functional delivery of mRNA and gene‑editing payloads for ex vivo and in vivo applications.
Aerosolized mRNA formulations for pulmonary preclinical use
Preclinical aerosolized mRNA formulations developed and evaluated for pulmonary administration to address lung inflammation and infection models.
Preclinical mesenchymal‑like cell therapy candidates
Cell therapy candidates derived via mRNA‑based reprogramming and directed differentiation workflows intended for preclinical evaluation in inflammatory and regenerative indications.
Preclinical engineered immune effector cell candidates
Defined immune cell populations produced from pluripotent or reprogrammed sources for oncology preclinical programs, including lymphocyte and macrophage‑like populations.
Delivery reagent families for nucleic acid applications
Chemical reagent families, including ionizable and fusogenic lipids and polymer reagents, developed to improve cellular uptake and functional delivery of mRNA and gene‑editing payloads for ex vivo and in vivo applications.
Aerosolized mRNA formulations for pulmonary preclinical use
Preclinical aerosolized mRNA formulations developed and evaluated for pulmonary administration to address lung inflammation and infection models.
Services
Contract research: gene‑editing and cell engineering
Partnered R&D engagements to design gene‑editing constructs, develop and characterize gene‑edited cell lines, and optimize nucleic acid delivery and differentiation protocols for preclinical programs.
Nucleic acid delivery and formulation development
Custom chemistry design, synthesis and in vitro/in vivo testing of lipid and polymer formulations for nucleic acid delivery, including tissue‑targeted and aerosolized approaches and data packages for co‑development or licensing.
Cell line development, differentiation and manufacturing support
Development and scale‑up of gene‑edited pluripotent cell lines, directed differentiation protocols, and bioreactor workflows; provision of facility access and process development for translational projects.
GMP manufacturing and cleanroom production services
GMP‑compliant cleanroom manufacturing services for mRNA, gene‑editing and engineered cell therapy projects, supporting nonclinical and clinical supply and enabling partner manufacturing timelines.
Licensing, strategic collaboration and manufacturing partnership services
Structuring and executing exclusive license agreements, sponsored research, co‑development partnerships and specialty manufacturing collaborations to advance platform technologies into partner development and commercialization.
Contract research: gene‑editing and cell engineering
Partnered R&D engagements to design gene‑editing constructs, develop and characterize gene‑edited cell lines, and optimize nucleic acid delivery and differentiation protocols for preclinical programs.
Nucleic acid delivery and formulation development
Custom chemistry design, synthesis and in vitro/in vivo testing of lipid and polymer formulations for nucleic acid delivery, including tissue‑targeted and aerosolized approaches and data packages for co‑development or licensing.
Cell line development, differentiation and manufacturing support
Development and scale‑up of gene‑edited pluripotent cell lines, directed differentiation protocols, and bioreactor workflows; provision of facility access and process development for translational projects.
GMP manufacturing and cleanroom production services
GMP‑compliant cleanroom manufacturing services for mRNA, gene‑editing and engineered cell therapy projects, supporting nonclinical and clinical supply and enabling partner manufacturing timelines.
Licensing, strategic collaboration and manufacturing partnership services
Structuring and executing exclusive license agreements, sponsored research, co‑development partnerships and specialty manufacturing collaborations to advance platform technologies into partner development and commercialization.
Expertise Areas
- mRNA therapeutics and construct engineering
- Non‑viral gene editing and endonuclease engineering
- In‑house gene‑editing platform development
- Nucleic acid delivery chemistry and formulation (including aerosolized pulmonary delivery)
Key Technologies
- mRNA construct design and synthesis
- Non‑viral gene‑editing platforms and engineered endonucleases
- Ionizable and fusogenic lipid chemistries for nucleic acid delivery
- Aerosolized pulmonary nucleic acid delivery methods